Empagliflozin - CAS# 864070-44-0 24726A Dougherty B

Dougherty B

Chemosensitivity examinations revealed that the UK5099 treated cells became more resistant to chemotherapy compared to the non-treated cells

216227-54-2

2-diylbis(azanediyl))bis(2-oxoethane-2

Murayama N

Empagliflozin - CAS# 864070-44-0 24726A Dougherty BEmpagliflozin, also known as BI10773 (trade name Jardiance), is drug approved for the treatment of type 2 diabetes in adults in 2014. It was developed by Boehringer Ingelheim and Eli Lilly and Company. Empagliflozin is an inhibitor of the sodium glucose co transporter 2 (SGLT 2), and causes sugar in the blood to be absorbed by the kidneys and eliminated in urine. Empagliflozin is an inhibitor of the sodium glucose co transporter 2 (SGLT 2), which is